# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

> **NCT02183311** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1356 BS - single rising dose
- **DRUG:** BI 1356 BS - multiple rising dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02183311
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-10
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183311, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*